Implantable 3D Printed Hydrogel Scaffolds Loading Copper-Doxorubicin Complexes for Postoperative Chemo/Chemodynamic Therapy.
Wentao DangYuqin WangWei-Chih ChenEnguo JuRachel L MintzYue TengLili ZhuKun WangShixian LvHon-Fai ChanYu TaoMingqiang LiPublished in: ACS applied materials & interfaces (2023)
Biomaterial-based implants hold great potential for postoperative cancer treatment due to the enhanced drug dosage at the disease site and decreased systemic toxicity. However, the elaborate design of implants to avoid complicated chemical modification and burst release remains challenging. Herein, we report a three-dimensional (3D) printed hydrogel scaffold to enable sustained release of drugs for postoperative synergistic cancer therapy. The hydrogel scaffold is composed of Pluronic F127 and sodium alginate (SA) as well as doxorubicin (DOX) and copper ions (F127-SA/Cu-DOX hydrogel scaffold). Benefiting from the coordination of Cu(II) with both SA and DOX, burst release of DOX can be overcome, and prolonged release time can be achieved. The therapeutic efficiency can be adjusted by altering the amount of DOX and Cu(II) in the scaffolds. Moreover, apoptosis and ferroptosis of cancer cells can be induced through the combination of chemotherapy and chemodynamic therapy. In addition, DOX supplies excess hydrogen peroxide to enhance the efficiency of Cu-based chemodynamic therapy. When implanted in the resection site, hydrogel scaffolds effectively inhibit tumor growth. Overall, this study may offer a new strategy for fabricating local implants with synergistic therapeutic performance for preventing postoperative cancer recurrence.
Keyphrases
- tissue engineering
- cancer therapy
- drug delivery
- hydrogen peroxide
- patients undergoing
- aqueous solution
- oxidative stress
- cell death
- nitric oxide
- soft tissue
- metal organic framework
- squamous cell carcinoma
- papillary thyroid
- bone marrow
- quantum dots
- emergency department
- squamous cell
- radiation therapy
- risk assessment
- combination therapy
- endothelial cells
- free survival
- adverse drug
- childhood cancer